Angiosuppression and chemotherapy: Strategies aimed at their integration in cancer patients

S. Cascinu, A. Valenti, M. Mesiti, G. Gasparini

Research output: Contribution to journalArticlepeer-review


A number of antiangiogenic agents have been developed as pharmaceuticals and are currently being rested in clinical studies. Potential strategies to enhance the activity of angiogenesis inhibitors could be to combine them, or better still, to administer them either sequentially or concurrently with cytotoxic drugs. Chemotherapy would be a more appropriate initial choice for patients with advanced disease since cytostatic agents can induce fast regression of the tumor and cancer-related symptoms. Antiangiogenic treatment could be used after chemotherapy in patients who achieve disease remission to prolong the time to progression, the symptom-free interval and the overall survival. Antiangiogenic treatment is likely to attain an important role in the adjuvant setting. In fact, it could be used for prolonged periods after radical surgery to maintain dormancy of residual tumor cells. In spite of these promising preclinical data, several points need to be clarified before the initiation of clinical trials. In fact, certain misconceptions may interfere with their optimum design and result analysis.

Original languageEnglish
Pages (from-to)239-242
Number of pages4
JournalInternational Journal of Biological Markers
Issue number4
Publication statusPublished - Oct 1999


  • Angiogenesis
  • Antiangiogenic therapy
  • Cancer
  • Chemotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology


Dive into the research topics of 'Angiosuppression and chemotherapy: Strategies aimed at their integration in cancer patients'. Together they form a unique fingerprint.

Cite this